R
R. Bart Sangal
Researcher at Oakland University
Publications - 37
Citations - 2952
R. Bart Sangal is an academic researcher from Oakland University. The author has contributed to research in topics: Attention deficit hyperactivity disorder & Polysomnography. The author has an hindex of 23, co-authored 36 publications receiving 2737 citations. Previous affiliations of R. Bart Sangal include Eli Lilly and Company & University of California, Irvine.
Papers
More filters
Journal ArticleDOI
Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study
David Michelson,Albert J. Allen,Joan Busner,Charles D. Casat,David W. Dunn,Christopher J. Kratochvil,Jeffrey H. Newcorn,F. Randy Sallee,R. Bart Sangal,Keith E. Saylor,Scott West,Douglas Kelsey,Joachim F. Wernicke,Nancy J. Trapp,Donald Harder +14 more
TL;DR: Once-daily administration of atomoxetine is an effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD) as assessed by investigator, parent, and teacher ratings.
Journal ArticleDOI
The clinical use of the MSLT and MWT.
Donna L. Arand,Michael H. Bonnet,Thomas D. Hurwitz,Merrill M. Mitler,Roger R. Rosa,R. Bart Sangal +5 more
TL;DR: The studies examined in this review indicate that the MSL is sensitive to conditions expected to increase sleepiness and shows appropriate change from initial testing to subsequent testing following treatment or manipulations intended to alter sleepiness or alertness.
Journal ArticleDOI
A normative study of the maintenance of wakefulness test (MWT).
Karl Doghramji,Merrill M. Mitler,R. Bart Sangal,Colin M. Shapiro,Sheila R. Taylor,Joyce A. Walsleben,Cynthia Belisle,Milton K. Erman,Rosa Hayduk,Rima Hosn,Edward B. O'Malley,JoAnne M. Sangal,Sharon L. Schutte,James M. Youakim +13 more
TL;DR: The maintenance of wakefulness test appears to be a useful procedure in differentiating groups with normal daytime wake tendency from those with impaired wake tendency and in identifying individuals with pathologic inability to remain awake under soporific circumstances.
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
Philip M. Becker,Andrew Jamieson,Carolyn E. Jewel,Richard K. Bogan,Donna S. James,Julie T. Sutton,Bruce Corser,David W. Mayleben,Shane H. Bernard,Dudley S. Dinner,Helene Emsellem,Elizabeth Knight,C. W. Erwin,Andrew D. Krystal,Rodney A. Radtke,Simon Farrow,Troy Odynski,John Pinto,Darlene Steljes,Neil T. Feldman,Mary O'Brien,Paul A. Fredrickson,Joseph Kaplan,Siong-Chi Lin,Charles D. Burger,June M. Fry,Christian Guilleminault,Jed Black,Philip M. Green,Linda Schmitigal,Paul T. Gross,Susan Dignan,John R. Harsh,Geoffrey Hartwig,J. Brevard Haynes,Martha Hageman,Ken Porter-Shirley,Gila Hertz,Max Hirshkowitz,Constance A. Moore,Vasudeva Iyer,Mark M. Mahowald,Constance Ullevig,Merrill M. Mitler,Roza Hayduk,Milton K. Erman,Ralph Pascualy,Sarah Stolz,Dallas Parman,Ralph W. Richter,Steven P. Gruenau,JoAnn J. Webster,Ruzica K. Ristanovic,Donna Bergen,Andres M. Kanner,Jane Dyonzak,Ann E. Rogers,Michael S. Aldrich,Russell Rosenberg,Tim Richardson,John Lee,Pradeep K. Sahota,James D. Dexter,Robert C. Burger,R. Bart Sangal,JoAnne M. Sangal,Cynthia Belisle,Helmut S. Schmidt,Peggy A. Parisot,Wolfgang W. Schmidt-Nowara,Carol Jessup,Jonathan R.L. Schwartz,Elliott R. Schwartz,Chris Veit,Liz Blakely,Lawrence Scrima,Bradford R. Miller,Shashidar M. Shettar,Roberta S. May,Karen E. Wilkerson,Calvin Stafford,Wendell A. Grogan,Robert Tearse,Stephen G. Thein,Linda Colontonio,Boris A. Vern,Patricia J. Mercer,Sharon L. Merritt,Joyce A. Walsleben,Mary B. O'Malley,David M. Rapoport,Andrew Winokur,Martin D. Szuba,Richard H. Civil,Thomas W. Dobbins,Nancy Barone Kribbs,Watson B. Laughton,Michael T. Nelson,Lixia Wang +98 more
TL;DR: In this article, the authors evaluated the efficacy and safety of modafinil, a novel wake-promoting agent, in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
Journal ArticleDOI
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W. Joseph Herring,Kathryn M. Connor,Neely Ivgy-May,Ellen Snyder,Ken Liu,Duane B. Snavely,Andrew D. Krystal,James K. Walsh,Ruth M. Benca,Russell Rosenberg,R. Bart Sangal,Kerry Budd,Jill Hutzelmann,Heather Leibensperger,Samar Froman,Christopher Lines,Thomas Roth,David Michelson +17 more
TL;DR: Suvorexant improved sleep onset and maintenance over 3 weeks of nightly treatment and was generally safe and well tolerated, with <5% of patients discontinuing due to adverse events over 3 months.